Disc Medicine, Inc.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company's mission is to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its corporate headquarters are located in Watertown, Massachusetts, United States.

The company's pipeline includes several therapeutic candidates targeting various hematologic disorders. Bitopertin is being developed for erythropoietic porphyrias (EPs), such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA). DISC-0974 is aimed at treating anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD), while DISC-3405 is in development for polycythemia vera (PV) and other related conditions. Additionally, preclinical programs include DISC-0998, which targets anemia associated with inflammatory diseases.

Led by President and CEO John Quisel, Disc Medicine submitted a New Drug Application (NDA) for bitopertin for accelerated approval in EPP in September 2025, which also received a Commissioner's National Priority Review Voucher. However, in February 2026, the company received a complete response letter from the FDA regarding this NDA, leading to a restructuring plan that included a 20% workforce reduction, primarily impacting commercial and support functions. Despite this, Disc Medicine remains well-capitalized, reporting over $800 million in cash as of December 2025, providing operational runway into 2029. The Phase 3 APOLLO study for bitopertin in EPP is expected to complete enrollment in March 2026, with topline data anticipated in Q4 2026.